Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal function effect of Tenofovir/Lamivudine/Dolutegravir vs Tenofovir/Emtricitabine/Rilpivirine in HIV patients
TCTR20241030006Completed
- Sponsor
- Department of Medicine
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tenofovir, lamivudine, dolutegravir, emtricitabine and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Department of Medicine. Primary endpoint: Renal function parameters. Started Jun 2023; status: completed.
02
Drugs
tenofovirlamivudinedolutegraviremtricitabinerilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20241030006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241030006.